Journal
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Volume 19, Issue 8, Pages 1888-1895Publisher
WILEY
DOI: 10.1111/jth.15332
Keywords
activation; ADAMTS‐ 13; autoantibody; inhibition; TTP; HUS
Categories
Funding
- National Heart, Lung, and Blood Institute [HL126724]
- Hemostasis and Thrombosis Research Society
Ask authors/readers for more resources
This study demonstrates that a human monoclonal antibody fragment isolated from a patient with acute iTTP can activate ADAMTS-13 and increase proteolytic cleavage, suggesting a potential role in modulating inhibition by other antibodies against ADAMTS-13. These findings provide new insights into the pathogenesis of iTTP.
Background Immune thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal thrombotic microangiopathy, resulting from a severe deficiency of plasma ADAMTS-13 (A Disintegrin And Metalloproteinase with ThromboSpondin type 1 motif, member 13) activity. IgG-type autoantibodies are primarily responsible for the inhibition of plasma ADAMTS-13 activity. However, the mechanism underlying autoantibody-mediated inhibition is not fully understood. Objective The purpose of the present study is to determine the role of IgG autoantibodies against various carboxyl-terminal domains of ADAMTS-13 in regulating ADAMTS-13 activity and its inhibition. Method Various human monoclonal antibodies isolated by phage display, recombinant protein expression and purification, and biochemical analyses were employed for the study. Results Our results demonstrate for the first time that a human monoclonal antibody fragment, the single chain fragment of the variable region (scFv) isolated from a patient with acute iTTP that binds the distal carboxyl-terminus of ADAMTS-13, is able to activate ADAMTS-13 and increase the proteolytic cleavage of a FRETS-VWF73 substrate; moreover, binding of such a human monoclonal antibody against the carboxyl-terminus of ADAMTS-13 to plasma ADAMTS-13 appears to modulate inhibition by another human monoclonal antibody (i.e., scFv4-20), also isolated from an iTTP patient, that targets the spacer domain of ADAMTS-13. These results provide new insights into our understanding of the pathogenesis of iTTP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available